Elevated Plasma F2-Isoprostanes Linked to Increased Fracture Risk in Type 2 Diabetes
Overview
This study demonstrates that higher plasma F2-isoprostanes, a marker of oxidative stress, are significantly associated with increased incident clinical fracture risk in older adults with type 2 diabetes (T2D), independent of bone mineral density (BMD). No such association was found in individuals without diabetes.
Background
Fracture risk is elevated in individuals with T2D despite similar BMD levels compared to non-diabetics, suggesting factors beyond BMD contribute to bone fragility in T2D. Oxidative stress, characterized by excess reactive oxygen species, is implicated in diabetic complications and may impair bone cell function, reducing bone quality. F2-isoprostanes are reliable biomarkers of oxidative stress and have been shown to increase in T2D, but their relationship with fracture risk in this population had not been previously explored.
Data Highlights
Parameter
T2D Group
Non-Diabetes Group
Sample Size (N)
132
571
Hazard Ratio per SD increase in log plasma F2-isoprostanes
1.93 (95% CI 1.26-2.9), P = .002
0.98 (95% CI 0.81-1.18), P = .79
Correlation with baseline total hip BMD
r = -0.25, P = .003
Not significant
Correlation with 4-year decrease in total hip BMD
r = -0.28, P = .008
Not significant
Key Findings
Each standard deviation increase in log plasma F2-isoprostanes was associated with a 93% higher risk of incident clinical fractures in older adults with T2D.
No significant association between plasma F2-isoprostanes and fracture risk was observed in individuals without diabetes.
Plasma F2-isoprostanes levels correlated moderately with lower baseline total hip BMD and greater 4-year BMD decline in the T2D group.
No correlation was found between plasma F2-isoprostanes and circulating glycoxidation or bone turnover markers in either group.
The association between oxidative stress and fracture risk in T2D was independent of baseline BMD and other clinical risk factors.
Clinical Implications
Measurement of plasma F2-isoprostanes may provide additional risk stratification for fractures in older adults with T2D beyond traditional BMD assessments. Targeting oxidative stress could represent a novel therapeutic approach to reduce bone fragility and fracture risk in this population. Clinicians should consider oxidative stress markers when evaluating fracture risk in patients with T2D.
Conclusion
Elevated plasma F2-isoprostanes, reflecting increased oxidative stress, are independently associated with higher fracture risk in older adults with type 2 diabetes. These findings highlight oxidative stress as a potential contributor to bone fragility in T2D beyond bone mineral density.
References
Health ABC Study -- Health, Aging, and Body Composition Study
Clinical Research Article -- Elevated Plasma F2-Isoprostanes Correlate with Higher Fracture Risk in Individuals with Type 2 Diabetes
